Skip to main content

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis

Abstract

Psoriasis is a chronic immune-mediated disease associated with several co-morbidities and negative impacts on a patient’s quality of life. Despite the advances in biologic therapy, there are still unmet needs in the treatment of psoriasis, as current treatments are limited in terms of long-term efficacy, tolerability, safety, route of administration, and cost. Apremilast is an oral, small-molecule phosphodiesterase 4 inhibitor that works intracellularly by blocking the degradation of cyclic adenosine 3′,5′-monophosphate, resulting in increased intracellular cyclic adenosine 3′,5′-monophosphate levels in phosphodiesterase 4-expressing cells. This inhibition results in the reduced expression of proinflammatory mediators, and an increased expression of anti-inflammatory mediators, providing apremilast with an anti-inflammatory rather than immunosuppressive mode of action. Apremilast offers a novel therapeutic option for patients with psoriasis and psoriatic arthritis and may fulfill some of the unmet needs in patients with psoriasis. Potential advantages of apremilast include moderate activity for both psoriasis and psoriatic arthritis and efficacy in difficult-to-treat forms of psoriasis, a good safety profile, no need of laboratory prescreening or ongoing monitoring for laboratory parameters, owing to the absence of organ toxicity, a potentially advantageous weight loss effect, and a convenient oral administration and dosing. Cost effectiveness and health economics considerations will be decisive in determining the ultimate place of apremilast in the therapeutic armamentarium for psoriasis.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386:983–94.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;2:31–5.

    Article  Google Scholar 

  3. 3.

    Carretero G, Ferrandiz C, Dauden E, Vanaclocha Sebastián F, Gómez-García FJ, Herrera-Ceballos E, et al. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry. J Eur Acad Dermatol Venereol. 2015;29:156–63.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Dávila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol. 2016;30:1942–50.

    PubMed  Google Scholar 

  5. 5.

    Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(871–81):e1–30.

    Google Scholar 

  6. 6.

    Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68:64–72.

    Article  PubMed  Google Scholar 

  7. 7.

    Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26:2016–29.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013;12:888–97.

    CAS  PubMed  Google Scholar 

  9. 9.

    Perez-Aso M, Montesinos MC, Mediero A, Wilder T, Schafer PH, Cronstein B, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015;17:249.

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Gooderham M, Papp K. Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast. BioDrugs Clin Immunother Biopharm Gene Ther. 2015;29:327–39.

    CAS  Google Scholar 

  11. 11.

    Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27:e376–83.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380:738–46.

    Article  Google Scholar 

  13. 13.

    Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387–99.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31:507–17.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74:134–42.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Nguyen CM, Leon A, Danesh M, Beroukhim K, Wu JJ, Koo J, et al. Improvement of nail and scalp psoriasis using apremilast in patients with chronic psoriasis: phase 2b and 3, 52-week randomized, placebo-controlled trial results. J Drugs Dermatol. 2016;15:272–6.

    CAS  PubMed  Google Scholar 

  18. 18.

    Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016;75:99–105.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Sobell JM, Foley P, Toth D, Mrowietz U, Girolomoni G, Goncalves J, et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol. 2016;96:514–20.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Mayba JN, Gooderham MJ. Real-world experience with apremilast in treating psoriasis. J Cutan Med Surg. 2017;21(2):145–51.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156–67.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Reed M, Crosbie D. Apremilast in the treatment of psoriatic arthritis: a perspective review. Ther Adv Musculoskelet Dis. 2017;9:45–53.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020–6.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42:479–88.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43:1724–34.

    Article  PubMed  Google Scholar 

  26. 26.

    Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065–73.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Wells A, Adebajo AO, Aelion JA, Bird P, Kivitz A, Lioté F, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in the signs and symptoms of psoriaticarthritis in DMARD-naive patients: results from a phase 3, randomized, controlled trial [abstract no. 1543]. Arthritis. Rheumatol. 2014;66(Suppl. 10):S680.

    Google Scholar 

  28. 28.

    Chiricozzi A, Caposiena D, Garofalo V, Cannizzaro MV, Chimenti S, Saraceno R. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast. Expert Rev Clin Immunol. 2016;12:237–49.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Crowley J, Thaçi D, Joly P, Peris K, Papp KA, Goncalves J, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017. doi:10.1016/j.jaad.2017.01.052 (Epub ahead of print).

    Google Scholar 

  30. 30.

    Busa S, Kavanaugh A. Drug safety evaluation of apremilast for treating psoriatic arthritis. Expert Opin Drug Saf. 2015;14:979–85.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Del Rosso JQ, Kircik L. Oral apremilast for the treatment of plaque psoriasis. J Clin Aesthetic Dermatol. 2016;9:43–8.

    Google Scholar 

  32. 32.

    European Medicines Agency. Otezla. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003746/human_med_001835.jsp&mid=WC0b01ac058001d124. Accessed 11 Mar 2017.

  33. 33.

    Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(11):CD002309. doi:10.1002/14651858.CD002309.pub4.

  34. 34.

    Wedzicha JA, Calverley PM, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:81–90.

    Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Celgene. Innovative therapies advancing treatment of diseases. 2013. http://www.celgene.com/therapies/. Accessed 11 Mar 2017.

  36. 36.

    Vakharia PP, Orrell KA, Lee D, Rangel SM, Lund E, Laumann AE, et al. Apremilast and suicidality: a retrospective analysis of three large databases: the FAERS, EudraVigilance and a large single-centre US patient population. J Eur Acad Dermatol Venereol. 2017. doi:10.1111/jdv.14256 (Epub ahead of print).

    Google Scholar 

  37. 37.

    Otezla® (apremilast): Nuevas recomendaciones en relación con el riesgo de ideación y conducta suicida. http://sinaem.agemed.es/CartasFarmacovigilanciaDoc/2016/DHPC_Otezla_Noviembre_2016_Final.pdf+&cd=2&hl=en&ct=clnk&gl=us&client=firefox-b-ab. Accessed 11 Mar 2017.

  38. 38.

    Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol. 2017. doi:10.1111/jdv.14301 (Epub ahead of print).

    Google Scholar 

  39. 39.

    Bianchi L, Del Duca E, Romanelli M, Saraceno R, Chimenti S, Chiricozzi A. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis. Expert Opin Drug Metab Toxicol. 2016;12:1121–8.

    CAS  Article  PubMed  Google Scholar 

  40. 40.

    Haebich G, Kalavala M. Successful treatment of refractory palmoplantar pustulosis with apremilast. Clin Exp Dermatol. 2017. doi:10.1111/ced.13065 (Epub ahead of print).

    PubMed  Google Scholar 

  41. 41.

    AbuHilal M, Walsh S, Shear N. Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study. J Cutan Med Surg. 2016;20:313–6.

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    ClinicalTrials.gov. http://clinicaltrials.gov/ct2/results?term=apremilast+psoriasis+real&Search=Search. Accessed 2 Jun 2017.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tiago Torres.

Ethics declarations

Funding

No sources of funding were received for the preparation of this article.

Conflict of interest

Tiago Torres has participated in clinical trials sponsored by AbbVie, Amgen, and Novartis and has received honoraria for acting as a consultant and/or as a speaker at events sponsored by AbbVie, Boehringer Ingelheim, Janssen, LeoPharma, MSD, Novartis, and Pfizer. Luis Puig has received consulting fees, speaking fees, and honoraria from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and Sun Pharma. His institution has received research funding in relationship to the treatment of psoriasis from AbbVie, Amgen, Janssen, Lilly, Novartis, and Pfizer.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Torres, T., Puig, L. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. Am J Clin Dermatol 19, 23–32 (2018). https://doi.org/10.1007/s40257-017-0302-0

Download citation